Q2 2026 13F · SEC CIK 1766721
Aisling Capital Management LP
Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $471.6M
- Reported positions
- 14
- Top holdings a year, 3 yrs
- +32.6%
- Assets under management
- $716.4M
Aisling Capital Management LP is a hedge fund that reported 14 positions worth $471.6M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Bridgebio Pharma Inc (BBIO, 72.5%), Monte Rosa Therapeutics Inc (GLUE, 8.0%), Syndax Pharmaceuticals Inc (SNDX, 6.1%). A portfolio copying its top holdings returned 32.6% a year over the last 3 years, against 20.4% for the S&P 500.
Aisling Capital Management LP holdings all 14 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| BBIOBridgebio Pharma Inc | 72.5% | -9.8% | $341.8M |
| GLUEMonte Rosa Therapeutics Inc | 8.0% | +0.0% | $37.6M |
| SNDXSyndax Pharmaceuticals Inc | 6.1% | +0.0% | $28.8M |
| CMPSCompass Pathways PLC | 4.3% | +0.0% | $20.3M |
| BCAXBicara Therapeutics Inc | 3.6% | +0.0% | $16.9M |
| BBOTBridgebio Oncology Therapeut | 1.6% | +0.0% | $7.8M |
| SRRKScholar Rock Hldg Corp | 0.9% | +0.0% | $4.2M |
| URGNUrogen Pharma Ltd | 0.8% | +0.0% | $4.0M |
| BMEABiomea Fusion Inc | 0.6% | +0.0% | $3.0M |
| ACRSAclaris Therapeutics Inc | 0.5% | +0.0% | $2.3M |
| EPRXEupraxia Pharmaceuticals Inc | 0.5% | +0.0% | $2.1M |
| VTVTVtv Therapeutics Inc | 0.4% | — | $1.9M |
| MRKRMarker Therapeutics Inc | 0.1% | +0.0% | $478K |
| OKUROnkure Therapeutics Inc | 0.1% | +0.0% | $404K |
What Aisling Capital Management LP bought and sold in Q2 2026, against Q1 2026.
New positions
- VTVT Vtv Therapeutics Inc0.4% of 13F
Added to
No position grew by more than 5%.
Reduced
- BBIO Bridgebio Pharma Inc-9.8% shares
Sold out
Nothing sold out.
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +56.1% /yr
- S&P 500 +20.1%
- 3 years
- +32.6% /yr
- S&P 500 +20.4%
- 5 years
- +9.4% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $471.6M | 14 |
| Q1 2026 | $476.3M | 13 |
| Q4 2025 | $478.9M | 13 |
| Q3 2025 | $456.4M | 14 |
| Q2 2025 | $359.7M | 13 |
| Q1 2025 | $288.5M | 13 |
| Q4 2024 | $281.8M | 15 |
| Q3 2024 | $261.1M | 16 |
| Q2 2024 | $231.1M | 15 |
| Q1 2024 | $295.5M | 16 |
| Q4 2023 | $335.2M | 16 |
| Q3 2023 | $242.7M | 17 |
Questions about Aisling Capital Management LP's portfolio
What stocks does Aisling Capital Management LP own?
Aisling Capital Management LP's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 14 positions worth $471.6M. The largest are Bridgebio Pharma Inc (BBIO) at 72.5%, Monte Rosa Therapeutics Inc (GLUE) at 8.0%, Syndax Pharmaceuticals Inc (SNDX) at 6.1%, Compass Pathways PLC (CMPS) at 4.3% and Bicara Therapeutics Inc (BCAX) at 3.6%.
What did Aisling Capital Management LP buy last quarter?
In Q2 2026, Aisling Capital Management LP added a new position in Vtv Therapeutics Inc (VTVT), compared with its Q1 2026 filing.
What did Aisling Capital Management LP sell last quarter?
In Q2 2026, Aisling Capital Management LP Bridgebio Pharma Inc (BBIO) (-9.8% shares), compared with its Q1 2026 filing.
How has Aisling Capital Management LP's portfolio performed?
A portfolio copying Aisling Capital Management LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +32.6% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +56.1% against +20.1%. Over 5 years: +9.4% a year against +11.6%.
When is Aisling Capital Management LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Aisling Capital Management LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Aisling Capital Management LP manage?
Aisling Capital Management LP reported $716.4M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $471.6M.